Panizo A, Pardo J, Hernández M, Galindo M F, Cenarruzabeitia E, Díez J
Department of Pathology, University Clinic, School of Medicine, Pamplona, Spain.
Am J Hypertens. 1995 Aug;8(8):815-22. doi: 10.1016/0895-7061(95)00120-E.
In genetic and acquired hypertension, a structural remodeling of the nonmyocyte compartment of myocardium, including the accumulation of fibrillar collagen and other components of the extracellular matrix (ECM) within the interstitium, represents a determinant of pathologic hypertrophy that leads to ventricular dysfunction. Therefore, to evaluate the potential benefit of the angiotensin converting enzyme (ACE) inhibitor quinapril in reversing the interstitial remodeling in spontaneously hypertensive rats (SHR) with established left ventricular hypertrophy (LVH), we treated 16-week-old male SHR with oral quinapril (average dose, 10 mg/kg body weight/day) for 20 weeks. Interstitial fibrosis was determined morphometrically using an automatic image analyzer. The amount of collagen was evaluated by measuring myocardial hydroxyproline concentration. Myocardial deposition of collagen molecules (types I, III, and IV) and other ECM components (fibronectin, laminin) was analyzed by immunohistochemical techniques using specific monoclonal antibodies. The activity of ACE was measured in left ventricular tissue by a fluorometric assay. In quinapril-treated SHR compared with 36-week-old untreated SHR and age- and sex-matched Wistar-Kyoto (WKY) controls, we found 1) a lesser degree of LVH and a lesser level of blood pressure, 2) a lesser degree of interstitial fibrosis, represented by less interstitial collagen volume fraction (5.73 +/- 0.45% v 3.42 +/- 0.28%, P < .05; WKY, 3.44 +/- 0.66%), 3) a lower hydroxyproline concentration (1.09 +/- 0.05 mumol/L/g dry weight/100 g body weight to 0.81 +/- 0.05 mumol/L/g dry weight/100 g body weight, P < .05; WKY, 0.96 +/- 0.06 mumol/L/g dry weight/100 g body weight), 4) a lesser presence of collagen fibers, and 5) a lesser presence of collagen IV, fibronectin, and laminin.(ABSTRACT TRUNCATED AT 250 WORDS)
在遗传性和后天性高血压中,心肌非心肌细胞成分的结构重塑,包括间质内纤维状胶原蛋白和细胞外基质(ECM)其他成分的积累,是导致病理性肥大进而引起心室功能障碍的一个决定因素。因此,为了评估血管紧张素转换酶(ACE)抑制剂喹那普利在逆转已发生左心室肥厚(LVH)的自发性高血压大鼠(SHR)间质重塑方面的潜在益处,我们对16周龄雄性SHR口服喹那普利(平均剂量,10 mg/kg体重/天),持续20周。使用自动图像分析仪通过形态计量学方法测定间质纤维化程度。通过测量心肌羟脯氨酸浓度来评估胶原蛋白含量。使用特异性单克隆抗体通过免疫组化技术分析胶原蛋白分子(I、III和IV型)和其他ECM成分(纤连蛋白、层粘连蛋白)在心肌中的沉积情况。通过荧光测定法测量左心室组织中ACE的活性。与36周龄未治疗的SHR以及年龄和性别匹配的Wistar-Kyoto(WKY)对照相比,在喹那普利治疗的SHR中,我们发现:1)左心室肥厚程度较轻且血压水平较低;2)间质纤维化程度较轻,表现为间质胶原蛋白体积分数较低(5.73±0.45%对3.42±0.28%,P<.05;WKY为3.44±0.66%);3)羟脯氨酸浓度较低(从1.09±0.05 μmol/L/g干重/100 g体重降至0.81±0.05 μmol/L/g干重/100 g体重,P<.05;WKY为0.96±0.06 μmol/L/g干重/100 g体重);4)胶原纤维的存在较少;5)IV型胶原蛋白、纤连蛋白和层粘连蛋白的存在较少。(摘要截短于250字)